Otsuka to Release Oral Vasopressin V2-receptor Antagonist Drug.Tokyo, Japan, Oct 12, 2006 - (JCN) - Otsuka Pharmaceutical Co., Ltd. has announced its development of Physuline 30mg, which will be released for the first time in Japan on October 24 of this year. Physuline is an oral vasopressin vasopressin (văz'ōprĕs`ĭn): see antidiuretic hormone. V2-receptor antagonist drug that has proven effective in patients with syndrome of inappropriate antidiuretic hormone The syndrome of inappropriate antidiuretic hormone (SIADH) is a condition commonly found in the hospital population, especially in patients being hospitalized for central nervous system (CNS) injury. (SIADH SIADH syndrome of inappropriate antidiuretic hormone. SIADH syndrome of inappropriate secretion of antidiuretic hormone. SIADH ), a condition resulting in fluid overload due to the excessive release of antidiuretic hormone. Physuline 30mg is effective for patients with SIADH caused by cancer-induced ectopic ectopic /ec·top·ic/ (ek-top´ik) 1. pertaining to ectopia. 2. located away from normal position. 3. arising from an abnormal site or tissue. ec·top·ic adj. antidiuretic hormone; in addition, marked improvement in hyponatremia Hyponatremia Definition The normal concentration of sodium in the blood plasma is 136-145 mM. Hyponatremia occurs when sodium falls below 130 mM. Plasma sodium levels of 125 mM or less are dangerous and can result in seizures and coma. for SIADH patients was noted. According to the clinical trial, the overall percentage of patients who experienced side effects was 39.3%. Major side effects were dry mouth (21.4%) and increases in AST (GOT), ALT (GPT) and serum potassium (7.1% each). Physuline is nevertheless a long-awaited drug, especially for patients who cannot get chemotherapy treatment due to hyponatremia. Physuline is priced at 8,734 yen per tablet Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion